Transgene Stock price

Equities

TNG

FR0005175080

Biotechnology & Medical Research

Real-time Euronext Paris 12:08:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.14 EUR +2.52% Intraday chart for Transgene -1.72% -16.79%
Sales 2023 7.9M 8.51M Sales 2024 * 39.8M 42.86M Capitalization 115M 123M
Net income 2023 -22M -23.69M Net income 2024 * -13M -14M EV / Sales 2023 17.4 x
Net Debt 2023 * 1.9M 2.05M Net Debt 2024 * 16.4M 17.66M EV / Sales 2024 * 3.29 x
P/E ratio 2023
-6.23 x
P/E ratio 2024 *
-8.14 x
Employees 143
Yield 2023 *
-
Yield 2024 *
-
Free-Float 34.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.52%
1 week-1.72%
Current month+9.62%
1 month+10.68%
3 months-16.91%
6 months-26.17%
Current year-16.79%
More quotes
1 week
1.10
Extreme 1.102
1.17
1 month
1.04
Extreme 1.04
1.20
Current year
1.03
Extreme 1.03
1.40
1 year
1.03
Extreme 1.03
2.55
3 years
1.03
Extreme 1.03
3.15
5 years
0.81
Extreme 0.81
3.39
10 years
0.81
Extreme 0.81
12.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 22-03-30
Director of Finance/CFO - 16-03-31
Chief Tech/Sci/R&D Officer 70 16-03-16
Members of the board TitleAgeSince
Director/Board Member 74 13-06-18
Director/Board Member 63 04-12-06
Director/Board Member 59 99-12-31
More insiders
Date Price Change Volume
24-03-28 1.14 +2.52% 56,363
24-03-27 1.112 +0.18% 18,392
24-03-26 1.11 +0.36% 5,793
24-03-25 1.106 -2.30% 23,777
24-03-22 1.132 -2.41% 3,802

Real-time Euronext Paris, March 28, 2024 at 12:08 pm EDT

More quotes
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.14 EUR
Average target price
3.5 EUR
Spread / Average Target
+207.02%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Transgene - Euronext Paris